Share of Clicks for top 10 US Pharma & Biotech Infectious Diseases brands
Here are the Top 10 competitors in the industry by Share of Clicks for the last month.
| Domain | Share of clicks |
|---|---|
| paxlovid.com | 22.68 |
| uqora.com | 11.37 |
| admired.com | 8.01 |
| mavyret.com | 7.32 |
| goodrx.com | 5.37 |
| cabenuva.com | 4.99 |
| prevnar20.com | 3.65 |
| symtuzahcp.com | 3.3 |
| abrysvoadult.pfizerpro.com | 3.26 |
| hellowisp.com | 2.79 |
| others | 27.26 |
- paxlovid.com - 22.68%
- uqora.com - 11.37%
- admired.com - 8.01%
- mavyret.com - 7.32%
- goodrx.com - 5.37%
- cabenuva.com - 4.99%
- prevnar20.com - 3.65%
- symtuzahcp.com - 3.3%
- abrysvoadult.pfizerpro.com - 3.26%
- hellowisp.com - 2.79%
- others - 27.26%
Copyright © Adthena. All rights reserved.
Paxlovid.com leads with 22.68% click share, followed by Uqora.com at 11.37%. Others collectively hold 27.26%, showcasing diverse competition.
Share of Spend for the top 10 US Pharma & Biotech Infectious Diseases brands
Curious about your market position? Here you can see the Top 10 competitors in the industry by Share of Spend for the last month.
| Date | cabenuva.com | uqora.com | admired.com | mavyret.com | prevnar20.com | symtuzahcp.com | paxlovid.com | dovato.com | gofreddie.com | goodrx.com |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/04/01 | 8.78% | 0% | 0% | 17.67% | 1.65% | 5.78% | 3.35% | 3.15% | 2.09% | 0% |
| 2026/04/02 | 16.57% | 0% | 0% | 9.88% | 0.07% | 7.73% | 7.95% | 6.67% | 2.57% | 0% |
| 2026/04/03 | 11.57% | 6.04% | 2.21% | 17.15% | 5.83% | 5.11% | 2.46% | 3.26% | 1.1% | 0% |
| 2026/04/04 | 16.6% | 6.71% | 3.51% | 13.9% | 4.3% | 6.66% | 1.58% | 4.06% | 1.21% | 0% |
| 2026/04/05 | 16.65% | 5.65% | 0.81% | 12.16% | 5.58% | 7.03% | 2.74% | 5.59% | 0.91% | 0% |
| 2026/04/06 | 12.98% | 0% | 1.23% | 14.4% | 5.62% | 7.53% | 9.58% | 4.57% | 4.64% | 0% |
| 2026/04/07 | 15.54% | 7.17% | 2.89% | 9% | 6.03% | 6.96% | 9.44% | 2.75% | 2.4% | 0% |
| 2026/04/08 | 13.2% | 0% | 0% | 14.5% | 5.65% | 7.47% | 6.73% | 5.38% | 2.55% | 0% |
| 2026/04/09 | 12.15% | 0% | 0% | 10.03% | 7% | 4.52% | 11.35% | 5.21% | 3.28% | 0% |
| 2026/04/10 | 11.03% | 14.14% | 9.25% | 5.75% | 4.9% | 3.8% | 8.46% | 2.21% | 2.67% | 6.13% |
| 2026/04/11 | 10.14% | 14.25% | 13.34% | 3.81% | 3.63% | 4.8% | 4.58% | 4.64% | 0.66% | 5.75% |
| 2026/04/12 | 8.25% | 12.28% | 14.09% | 4.59% | 2.64% | 3.56% | 8.36% | 1.92% | 2.62% | 8.63% |
| 2026/04/13 | 9.44% | 11.79% | 12.58% | 11.48% | 3.22% | 7.33% | 0.92% | 4.5% | 1.45% | 7.71% |
| 2026/04/14 | 6.67% | 7.69% | 9.16% | 5.18% | 4.97% | 4.45% | 5.7% | 9.22% | 2.18% | 6.75% |
| 2026/04/15 | 7.54% | 7.98% | 10.42% | 10.38% | 4.74% | 4.67% | 5.99% | 3.27% | 3.38% | 6.97% |
| 2026/04/16 | 2.26% | 21.77% | 12.95% | 3.51% | 4.37% | 3.49% | 7.12% | 4.44% | 1.06% | 7.9% |
| 2026/04/17 | 13.02% | 13.12% | 5.71% | 4.34% | 6.53% | 5.27% | 3.18% | 4.35% | 3.78% | 6.68% |
| 2026/04/18 | 13.63% | 8.02% | 6.27% | 3.26% | 4.56% | 5.44% | 9.79% | 6.98% | 1.31% | 8% |
| 2026/04/19 | 12.35% | 10.41% | 10.84% | 4.16% | 2.44% | 4.77% | 9.35% | 2.74% | 1.07% | 6.71% |
| 2026/04/20 | 14.3% | 9.98% | 6.24% | 4.11% | 4.19% | 8.74% | 1.43% | 8.49% | 2.64% | 5.13% |
| 2026/04/21 | 9.06% | 2.32% | 1.13% | 8.65% | 5.22% | 5.98% | 13.93% | 7.27% | 3.34% | 7.28% |
| 2026/04/22 | 14.9% | 0% | 0% | 8.63% | 5.32% | 5.67% | 15.16% | 3.44% | 6.1% | 0.3% |
| 2026/04/23 | 21.27% | 0% | 0% | 5.87% | 5.67% | 6.23% | 8% | 4.24% | 7.41% | 0.36% |
| 2026/04/24 | 19.41% | 0% | 0% | 4.71% | 4.92% | 3.21% | 8.81% | 6.81% | 2.97% | 0.76% |
| 2026/04/25 | 19.8% | 0% | 0% | 4.12% | 6.98% | 5.87% | 7.33% | 4.81% | 4.18% | 0.07% |
| 2026/04/26 | 19.83% | 0% | 0% | 7.09% | 4.85% | 2.5% | 12.45% | 6.05% | 6.71% | 0.4% |
| 2026/04/27 | 17.41% | 3.3% | 3.1% | 5.25% | 4.61% | 2.2% | 12.73% | 4.19% | 7.6% | 1.98% |
| 2026/04/28 | 23.07% | 0% | 0% | 5.96% | 4.39% | 3.69% | 10% | 7.38% | 3.04% | 0.52% |
| 2026/04/29 | 14.31% | 6.58% | 9.2% | 5.75% | 4.24% | 3.41% | 6.91% | 3.7% | 3.04% | 1.49% |
| 2026/04/30 | 19.25% | 11.51% | 10.62% | 7.76% | 4.97% | 4.96% | 4.34% | 4.15% | 3.69% | 1.55% |
- cabenuva.com
- uqora.com
- admired.com
- mavyret.com
- prevnar20.com
- symtuzahcp.com
- paxlovid.com
- dovato.com
- gofreddie.com
- goodrx.com
Copyright © Adthena. All rights reserved.
Cabenuva.com led April’s PPC spend, peaking at 23.07% on April 28. Uqora.com surged mid-month, reaching 21.77% on April 16. Admired.com saw a steady rise, while Mavyret.com fluctuated. By month’s end, Cabenuva.com dominated.
Competitor Count for US Pharma & Biotech Infectious Diseases
Ever wondered how many competitors you’re up against in your industry? Well look no further, here we can see the number of advertisers bidding over the last month.
| Date | Competitor Count |
|---|---|
| 2026/04/01 | 62 |
| 2026/04/02 | 61 |
| 2026/04/03 | 66 |
| 2026/04/04 | 68 |
| 2026/04/05 | 72 |
| 2026/04/06 | 68 |
| 2026/04/07 | 72 |
| 2026/04/08 | 71 |
| 2026/04/09 | 69 |
| 2026/04/10 | 75 |
| 2026/04/11 | 77 |
| 2026/04/12 | 78 |
| 2026/04/13 | 76 |
| 2026/04/14 | 74 |
| 2026/04/15 | 76 |
| 2026/04/16 | 70 |
| 2026/04/17 | 68 |
| 2026/04/18 | 72 |
| 2026/04/19 | 77 |
| 2026/04/20 | 71 |
| 2026/04/21 | 71 |
| 2026/04/22 | 71 |
| 2026/04/23 | 67 |
| 2026/04/24 | 70 |
| 2026/04/25 | 68 |
| 2026/04/26 | 63 |
| 2026/04/27 | 67 |
| 2026/04/28 | 71 |
| 2026/04/29 | 68 |
| 2026/04/30 | 65 |
Copyright © Adthena. All rights reserved.
April saw a dynamic shift in distinct advertisers, starting at 62 and peaking at 78 mid-month. The month concluded with a slight decline, ending at 65.
